March 14, 2011
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking|
|Frame PrEP as Part of a 'Healthy Sex Life' for Better Adherence|
|A New Nuke in the Works -- GS-9131|
|Bictegravir in the Body -- Preliminary Information About Drug Interactions|
|Running a PrEP Clinic in a Community Pharmacy Setting|